8/19/2019 9:28:50 AM
Pulmatrix Receives Grant From USPTO For US Pat. No. 10376465
8/5/2019 9:04:03 AM
Pulmatrix Q2 Net Loss $7.8 Mln Vs.net Loss $6.2 Mln Prior Year
5/16/2019 9:15:35 AM
Pulmatrix CEO Robert Clarke Steps Down
4/3/2019 9:34:06 PM
Pulmatrix Announces Pricing Of $14.4 Million Upsized Public Offering
3/12/2019 12:28:31 PM
Pulmatrix Regains NASDAQ Compliance
2/8/2019 7:07:31 AM
Pulmatrix Announces $2.5 Mln Registered Direct Offering Priced At-the-Market
2/7/2019 9:04:29 AM
Pulmatrix Gets IND Approval For Pulmazole Phase 2 Clinical Study
2/5/2019 12:45:56 PM
Pulmatrix Announces 1-for-10 Reverse Stock Split
2/5/2019 11:29:34 AM
Pulmatrix Announces Closing Of Public Offering Of Common Stock
1/31/2019 1:31:17 PM
Pulmatrix Announces Closing Of Public Offering Of Common Stock
1/30/2019 10:08:06 PM
Pulmatrix Prices Underwritten Public Offering Of 5.32 Mln Shares At $0.17/shr
1/30/2019 4:11:48 PM
Pulmatrix Announces Proposed Public Offering Of Common Stock
1/28/2019 11:33:14 PM
Pulmatrix Reports Pricing Of Public Offering Of 1.56 Mln Shares At $0.17/Shr
1/28/2019 4:19:14 PM
Pulmatrix Announces Proposed Public Offering Of Common Stock
11/29/2018 5:03:51 AM
Pulmatrix Enters Deal For Purchase And Sale Of 9.375 Mln Shares At $0.32/Shr In Registered Direct Offering
11/21/2018 9:30:55 AM
Pulmatrix Announces Positive Final Results From The Phase 1/1b Clinical Trial Of Pulmazole
9/17/2018 9:45:04 AM
Pulmatrix To Present Pre-clinical Data On PUR1800 At EPS International Congress
7/17/2018 9:03:21 AM
Pulmatrix Announces Positive Preliminary Results From Part 3 Of 3-Part Phase 1/1b Clinical Trial Of Pulmazole